SCHEMBL3980901

SCHEMBL3980901

O=C(O)C1C=CC=C2C1C(=O)OC21c2cc(F)c(O)cc2Oc2cc(O)c(F)cc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8336070 0.87 FTO (0.32)
SCHEMBL12986496 0.82 FTO (0.43)
SCHEMBL4295455 0.72
SCHEMBL7969779 0.70
SCHEMBL7971304 0.68
SCHEMBL3705213 0.67 FTO (0.44)
SCHEMBL3656489 0.64 FTO (0.44)
SCHEMBL408340 0.62 MAPT (0.64)
SCHEMBL7959704 0.62 FTO (0.38)
SCHEMBL30218785 0.62 MAPT (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3094318-B1 NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY KANNALIFE SCIENCES INC (US) 2020-02-19 EP disclosed
US-10004722-B2 Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols KANNALIFE SCIENCES, INC. (US) 2018-06-26 US disclosed
US-20170157097-A1 METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS KANNALIFE SCIENCES, INC. 2017-06-08 US disclosed
US-9611213-B2 Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy KANNALIFE SCIENCES, INC. (US) 2017-04-04 US disclosed
EP-3094318-A2 NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY Kannalife, Inc. (US) 2016-11-23 EP disclosed
US-20160311769-A1 NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY KANNALIFE SCIENCES, INC. 2016-10-27 US disclosed
WO-2015106108-A2 NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY KANNALIFE, INC. (US) 2015-07-16 WO disclosed
US-20130253022-A1 NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2013-09-26 US disclosed
WO-2012074784-A2 NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE ADVANCED NEURAL DYNAMICS, INC. (US) 2012-06-07 WO disclosed
WO-2009059244-A2 CELL-BASED ANTIOXIDANT PROTECTION ASSAY NATURAL IMMUNE SYSTEMS, INC. (US) 2009-05-07 WO disclosed
US-20080187502-A1 ASSESSMENT AND MITIGATION OF OXIDATIVE STRESS IN SKIN GARAY MICHELLE 2008-08-07 US disclosed
EP-1953548-A2 Assessment and mitigation of oxidative stress in skin Johnson & Johnson Consumer Companies, Inc. (US) 2008-08-06 EP disclosed